Lucas Capital Management lowered its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 3.1% during the third quarter, HoldingsChannel.com reports. The fund owned 67,386 shares of the biopharmaceutical company’s stock after selling 2,185 shares during the quarter. Bristol-Myers Squibb makes up about 3.8% of Lucas Capital Management’s portfolio, making the stock its 4th biggest holding. Lucas Capital Management’s holdings in Bristol-Myers Squibb were worth $4,295,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Xact Kapitalforvaltning AB increased its holdings in Bristol-Myers Squibb by 3.4% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 286,425 shares of the biopharmaceutical company’s stock valued at $15,960,000 after buying an additional 9,310 shares during the period. Boltwood Capital Management increased its holdings in Bristol-Myers Squibb by 1.7% in the 2nd quarter. Boltwood Capital Management now owns 18,205 shares of the biopharmaceutical company’s stock valued at $1,014,000 after buying an additional 300 shares during the period. Trust Co increased its holdings in Bristol-Myers Squibb by 1.8% in the 1st quarter. Trust Co now owns 54,428 shares of the biopharmaceutical company’s stock valued at $2,960,000 after buying an additional 969 shares during the period. Carlton Hofferkamp & Jenks Wealth Management LLC increased its holdings in Bristol-Myers Squibb by 12.7% in the 2nd quarter. Carlton Hofferkamp & Jenks Wealth Management LLC now owns 8,900 shares of the biopharmaceutical company’s stock valued at $495,000 after buying an additional 1,000 shares during the period. Finally, First Command Bank increased its holdings in Bristol-Myers Squibb by 3.1% in the 2nd quarter. First Command Bank now owns 3,302 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 100 shares during the period. 69.67% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Vetr lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 price target on the stock. in a report on Thursday, December 28th. BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a report on Monday, December 11th. Citigroup set a $72.00 price target on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a report on Tuesday, December 5th. Finally, SunTrust Banks raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Monday, October 30th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average target price of $65.05.

Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $62.81 on Friday. Bristol-Myers Squibb Co has a 52 week low of $46.01 and a 52 week high of $66.10. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The company has a market cap of $102,801.13, a price-to-earnings ratio of 21.22, a PEG ratio of 2.30 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The firm had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same quarter in the prior year, the firm posted $0.77 EPS. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. sell-side analysts expect that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be paid a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 2.55%. The ex-dividend date of this dividend is Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s payout ratio is currently 62.99%.

In related news, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the transaction, the executive vice president now owns 584,373 shares in the company, valued at approximately $37,031,717.01. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the transaction, the executive vice president now owns 9,251 shares in the company, valued at approximately $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.thecerbatgem.com/2018/01/14/lucas-capital-management-sells-2185-shares-of-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related stocks with our FREE daily email newsletter.